Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Tazbentetol

Source date not recordedAnalyse record ↗

Synaptic-regeneration small molecule with completed-enrollment Phase 2 studies and a registered Phase 2/3 ALS study not yet recruiting.

Modality
oral small-molecule transient activator of glutamatergic synapses
Availability (US)
Phase 2 Alzheimer and schizophrenia studies Active, not recruiting; Phase 2/3 ALS study Not yet recruiting
Biomarkers
adverse events; cognitive and functional scales; motor outcomes; pharmacokinetics; synaptic and fluid biomarkers
Hallmark targeted
altered intercellular communication, synapse loss, neuronal repair
Kind
investigational drug
Clinical trials
NCT06427668 — Phase 2 Alzheimer study Active, not recruiting; NCT06442462 — Phase 2 schizophrenia study Active, not recruiting; NCT07325591 — Phase 2/Phase 3 ALS study Not yet recruiting on September 10, 2026 update